Publication date: Aug 01, 2023
Coronavirus Disease 2019 (COVID-19) is characterized by an increased risk of thrombotic and hemorrhagic events resulting from endothelial dysfunction. In patients with ST-elevation myocardial infarction (STEMI), the dual antiplatelet therapy used to reduce mortality may increase the risk of bleeding. The study aimed to compare the efficacy and safety profiles of P2Y12 inhibitors used during the COVID-19 era. Three hundred and ninety patients who underwent primary percutaneous intervention for STEMI between January 1, 2020, and December 31, 2021, were included in this study, retrospectively. The patients were divided into groups according to their COVID-19 history and all-cause mortality, cardiac mortality, stent thrombosis, and bleeding complications during hospitalization and at one-year follow-up were compared. The mean age of the patients was 64. 3 years and the mean follow-up period was 10. 2 months; 80% of the patients were male and 44. 6% had a history of COVID-19 infection. The in-hospital mortality rate was 11. 3%. Cardiac mortality was significantly higher in the clopidogrel group compared to the other groups, regardless of COVID-19 history (21. 9% in the clopidogrel group, 1. 6% in the prasugrel group, and 6. 7% in the ticagrelor group (p
| Concepts | Keywords |
|---|---|
| Coronavirus | acute coronary syndrome |
| December | antiplatelet agents |
| Hospitalization | covid-19 |
| Ninety | mortality |
| thrombosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Myocardial Infarction |
| disease | MESH | COVID-19 |
| disease | MESH | STEMI |
| disease | MESH | bleeding |
| disease | IDO | intervention |
| disease | IDO | history |
| disease | MESH | thrombosis |
| disease | MESH | complications |
| disease | MESH | infection |
| drug | DRUGBANK | Clopidogrel |
| drug | DRUGBANK | Prasugrel |
| drug | DRUGBANK | Ticagrelor |
| disease | MESH | acute coronary syndrome |